Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 38.8%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 93,300 shares, a decline of 38.8% from the December 15th total of 152,400 shares. Based on an average daily trading volume, of 111,600 shares, the short-interest ratio is presently 0.8 days. Approximately 2.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th.

Brainstorm Cell Therapeutics Stock Down 2.9 %

Shares of Brainstorm Cell Therapeutics stock traded down $0.06 during trading hours on Thursday, reaching $1.99. 43,000 shares of the company’s stock were exchanged, compared to its average volume of 56,270. The business has a fifty day moving average of $1.77 and a two-hundred day moving average of $3.20. The company has a market capitalization of $11.34 million, a P/E ratio of -0.41 and a beta of 0.29. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.